Nat Rev Gastroenterol Hepatol 14(1):921 Phillip Dellinger R, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S et al (2009) Efficacy and safety of a phospholipid emulsion (GR270773) in gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial
In another, a lifespan trial in Swiss-derived SHR mice (1 g/mouse per month) reported no changes in food intake or body weight, while chromosomal aberrations decreased and maximum lifespan increased [7]
The claim that "over 75% of patients achieve significant pain relief without surgery" with peptide therapy comes from clinical observations, not controlled trials
[20] [19] In older or sarcopenic patients, preservation of lean mass is a major clinical goal
not primarily appetite-driven (OUP Academic) Expected weight loss (this is where many people get misled) In major obesity trials: Semaglutide 2.4 mg weekly: ~14.9% mean weight loss at 68 weeks (STEP-1) (PubMed) Tirzepatide: ~15.0% to ~20.9% mean weight loss at 72 weeks , dose-dependent (SURMOUNT-1) (PubMed) AOD-9604s best-known human signal is kilograms, not double-digit percentages , and later studies did not sustain a strong obesity-drug profile